Depositary Receipts allow companies and investors around the globe to connect seamlessly across borders.
160 billion DRs valued at $3.1 trillion traded Over $9.9 billion raised through 41 DR offerings 58 new sponsored DR programs created 59 new unsponsored DR programs created 3,602 total DR programs in existence
Click to read the full report>>
DRs AND THE PHARMA BIOTECH / HEALTH CARE SECTORS
An active area of recent U.S. investor interest has been the Pharmaceuticals & Biotechnology / Health Care Equipment & Services sectors. As of June 30, 2015, Pharma & Biotech / Health Care companies were the most active issuers of new ADR programs to day. BNY Mellon Depositary Receipts is focused on the unique needs of ADR issuers in these sectors.
For more information, read our latest brochure: The Benefits of Utilizing Depositary Receipts - Pharmaceuticals & Biotechnology / Health Care Equipment & Services Sectors.
Click to read the brochure>>
BNY Mellon DRs Proudly Announces the Launch of
ESG ADVISORY SOLUTIONS
Our objective is to assist issuer clients in developing an effective ESG strategy, fully integrated into their capital markets and investor relations activities. As market developments provide new risks and opportunities, we want to ensure our clients are at the forefront of understanding how best to respond to these developments.
Read our brochure and click on the video featuring Guy Gresham, Global IR Advisory Head at BNY Mellon Depositary Receipts.